What VELCADE contains
- The active substance is bortezomib. Each vial contains 1 mg or 3.5 mg of bortezomib (as a mannitol boronic ester). After reconstitution, 1 ml of solution for injection contains 1 mg bortezomib.
- The other ingredients are mannitol (E421) and nitrogen.
What VELCADE looks like and contents of the pack
VELCADE powder for solution for injection is a white to off-white cake or powder.
Each carton of VELCADE 1 mg powder for solution for injection contains a glass vial with a green cap, in a transparent blister pack.
Each carton of VELCADE 3.5 mg powder for solution for injection contains a glass vial with a royal blue cap, in a transparent blister pack.
Marketing Authorization Holder
JANSSEN-CILAG INTERNATIONAL N.V.
Turnhoutseweg, 30
B-2340 Beerse
Belgium
Manufacturer
Janssen Pharmaceutica N.V.
Turnhoutseweg 30
B-2340 Beerse
Belgium
For any information about this product, please contact the local representative of the Marketing Authorisation Holder.
BelgiëBelgiqueBelgien JANSSEN-CILAG NVSA Antwerpseweg 15-17 B-2340 Beerse TélTel 32 14 64 94 11 LuxembourgLuxemburg JANSSEN-CILAG NVSA Antwerpseweg 15-17 B-2340 Beerse BelgiqueBelgien Tél 32 14 64 94 11
Magyarország JANSSEN-CILAG Kft. H-2045 Törökbálint, Tó Park Tel 36 23-513-800 Johnson Johnson d.o.o. , 4, 4, 3 1715 . 359 2 489 94 00
eská republika JANSSEN-CILAG s.r.o. Karla Englie 32016 CZ-15000 Praha 5- Smíchov eská republika Tel 420 227 012 222 Malta A.M. Mangion Ltd. Mangion Building Triq dida fi triq Valletta Luqa LQA 6000 Malta TEL 00356 2397 60006412
Nederland JANSSEN-CILAG B.V. Postbus 90240 NL-5000 LT Tilburg Tel 31 13 583 73 73 Danmark JANSSEN-CILAG AS Hammerbakken 19 Postboks 149 DK-3460 Birkerød Tlf 45 45 94 82 82
Deutschland Janssen-Cilag GmbH Johnson Johnson Platz 1 D-41470 Neuss Tel 49 2137-955-0 Norge JANSSEN-CILAG A.S. Drammensveien 288 N-0283 Oslo Tlf 47 24 12 65 00
Österreich JANSSEN-CILAG Pharma Pfarrgasse 75 A-1232 Wien Tel43 1 610 300 Eesti Janssen-Cilag Polska Sp.z.o.o Eesti filiaal Lõõtsa 2 EE-11415 Tallinn Tel 372 617 7410
JANSSEN-CILAG .... 56 GR-151 21 T 30 210 80 90 000 Polska JANSSENCILAG POLSKA SP. Z O.O., WINIOWY BUSINESS PARK BUILDING F UL. IECKA 24 02-135 WARSAW POLAND Tel. 48 22 237 60 00
España JANSSEN-CILAG, S.A. Paseo de las Doce Estrellas, 5-7 Campo de las Naciones E-28042 Madrid Tel 34 91 722 81 00 Portugal JANSSEN-CILAG FARMACÊUTICA, LDA. Estrada Consiglieri Pedroso, 69 A Queluz de Baixo P-2734-503 Barcarena Tel 351 21 43 68 835
România Johnson Johnson d.o.o. Str. Tipografilor nr. 11-15 Cldirea S-Park, Corp A2, Etaj 013714 Bucureti, ROMANIA France JANSSEN-CILAG 1, rue Camille Desmoulins TSA 91003 F-92787 Issy Les Moulineaux Cedex 9 Tél 0 800 25 50 75 33 1 55 00 44 44 Tel 40 21 207 18 00
Slovenija Johnson Johnson d.o.o. martinska cesta 53 SI-1000, Ljubljana Tel. 386 1 401 18 30 Ireland JANSSEN-CILAG Ltd. 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG United Kingdom Tel 44 1 494 567 567
Slovenská republika Johnson Johnson s.r.o. Plynárenska 7B SK- 824 78 Bratislava 26 Tel 421 233 552 600 Ísland JANSSEN-CILAG co Vistor Hörgatún 2 IS-210 Garðabær Sími 354 535 7000
Italia JANSSEN-CILAG SpA Via M.Buonarroti, 23 I-20093 Cologno Monzese MI Tel 39 022510.1 SuomiFinland JANSSEN-CILAG OY VaisalantieVaisalavägen 2 FIN-02130 EspooEsbo PuhTel 358 20 753 1300
7 CY-1060 T 357 22 755 214 Sverige JANSSEN-CILAG AB Box 7073 S-192 07 Sollentuna Tel 46 8 626 50 00
Latvija United Kingdom
JANSSEN-CILAG Polska Sp. z o.o. fili-le Latvij- JANSSEN-CILAG Ltd.
Matro-u iela 15, LV-1048, R-ga 50-100 Holmers Farm Way T-lr. +371 678 93561 High Wycombe
Buckinghamshire HP12 4EG - UK Tel: +44 1 494 567 567
Lietuva
UAB ?Johnson & Johnson?
Gele-inio Vilko g. 18A
LT-08104 Vilnius
Tel: +370 5 278 68 88
This leaflet was last approved in
This medicinal product has been authorised under ?Exceptional Circumstances?. This means that for scientific reasons it has not been possible to obtain complete information on this medicinal product. The European Medicines Agency (EMA) will review any new information which may become available every year and this leaflet will be updated as necessary.
-------------------------------------------------------------------------------------------------------------------------
INFORMATION FOR MEDICAL OR HEALTHCARE PROFESSIONALS ONLY:
1. RECONSTITUTION
Note: VELCADE is a cytotoxic agent. Therefore, caution should be used during handling and preparation. Use of gloves and other protective clothing to prevent skin contact is recommended.
ASEPTIC TECHNIQUE MUST BE STRICTLY OBSERVED THROUGHOUT HANDLING OF VELCADE SINCE NO PRESERVATIVE IS PRESENT.
1.1. a) Preparation of the 1 mg vial: add 1.0 ml of sterile, 9 mg/ml (0.9%) sodium chloride
solution for injection to the vial containing the VELCADE powder.
b) Preparation of the 3.5 mg vial: add 3.5 ml of sterile, 9 mg/ml (0.9%) sodium chloride solution for injection to the vial containing the VELCADE powder.
The concentration of the resulting solution will be 1 mg/ml. The solution will be clear and colourless, with a final pH of 4 to 7. You do not need to check the pH of the solution.
1.2. Before administration, visually inspect the solution for particulate matter and discolouration. If
any discolouration or particulate matter is observed, the reconstituted product should be discarded.
1.3. The reconstituted product is preservative free and should be used immediately after preparation.
However, the chemical and physical in-use stability has been demonstrated for 8 hours at 25 °C stored in the original vial and/or a syringe prior to administration, with a maximum of 8 hours in the syringe. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
It is not necessary to protect the reconstituted medicinal product from light.
2. ADMINISTRATION
- Check the dose in the syringe.
- Inject the solution as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter into a vein.
- Flush the peripheral or intravenous catheter with sterile, 9 mg/ml (0.9%) sodium chloride solution.
3. DISPOSAL
A vial is for single use only and remaining solution must be discarded.
Any unused product or waste material should be disposed of in accordance with local requirements.